Calidi Biotherapeutics (CLDI) Competitors $0.34 +0.09 (+39.47%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.54 +0.21 (+61.79%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. ENLV, INKT, COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, and LSTAShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Enlivex Therapeutics (ENLV), MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Enlivex Therapeutics MiNK Therapeutics Coeptis Therapeutics China SXT Pharmaceuticals SCYNEXIS NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Is ENLV or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Calidi Biotherapeutics N/A N/A -344.45% Which has more volatility & risk, ENLV or CLDI? Enlivex Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do analysts prefer ENLV or CLDI? Enlivex Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 747.46%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in ENLV or CLDI? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, ENLV or CLDI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.79Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Does the media refer more to ENLV or CLDI? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 1 mentions for Calidi Biotherapeutics and 0 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Calidi Biotherapeutics' score of -0.30 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Enlivex Therapeutics Neutral Calidi Biotherapeutics Neutral SummaryEnlivex Therapeutics beats Calidi Biotherapeutics on 8 of the 12 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$10.65M$209.15M$5.47B$20.52BDividend YieldN/AN/A5.25%3.78%P/E RatioN/AN/A27.0027.79Price / SalesN/A259.79428.9540.48Price / CashN/A22.4436.8222.26Price / Book-0.145.707.984.58Net Income-$29.22M-$96.61M$3.16B$982.91M7 Day Performance43.22%4.68%2.39%0.41%1 Month Performance2.13%0.60%2.18%3.59%1 Year Performance-77.74%9.39%33.82%14.47% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.4661 of 5 stars$0.34+39.5%N/A-79.3%$10.65MN/A0.0038News CoverageGap UpHigh Trading VolumeENLVEnlivex Therapeutics3.1642 of 5 stars$1.12-6.7%$10.00+792.9%-11.9%$28.38MN/A-1.7070Positive NewsINKTMiNK Therapeutics2.6866 of 5 stars$7.34+5.2%$37.50+410.9%-19.1%$27.82MN/A-2.9130News CoverageGap UpCOEPCoeptis Therapeutics0.1958 of 5 stars$7.80+0.3%N/A+45.3%$27.34MN/A-1.342News CoverageSXTCChina SXT Pharmaceuticals0.1482 of 5 stars$1.73+0.6%N/A-79.1%$27.22M$1.82M0.0090News CoverageSCYXSCYNEXIS0.258 of 5 stars$0.67-2.4%N/A-63.0%$26.98M$3.75M-1.2060Positive NewsNRSNNeuroSense Therapeutics1.6928 of 5 stars$1.89-0.5%$14.00+640.7%+84.2%$25.97MN/A-3.5010TPSTTempest Therapeutics1.7145 of 5 stars$6.80-1.4%$30.00+341.2%-72.7%$25.41MN/A-0.3820CARACara Therapeutics0.338 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.2571 of 5 stars$5.76-1.5%$17.50+203.8%+81.7%$24.27MN/A-2.329LSTALisata Therapeutics2.4839 of 5 stars$2.90+3.6%$15.00+417.2%-16.2%$24.12M$1M-1.2630Gap Down Related Companies and Tools Related Companies Enlivex Therapeutics Competitors MiNK Therapeutics Competitors Coeptis Therapeutics Competitors China SXT Pharmaceuticals Competitors SCYNEXIS Competitors NeuroSense Therapeutics Competitors Tempest Therapeutics Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
